TCDA - Tricida, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Tricida, Inc.

7000 Shoreline Court
Suite 201
South San Francisco, CA 94080
United States
415 429 7800
http://www.tricida.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees141

Key Executives

NameTitlePayExercisedYear Born
Dr. Gerrit KlaernerFounder, Pres, CEO & Exec. Director973.69kN/A1971
Mr. Geoffrey M. ParkerCFO & Exec. VP621.02k1.74M1965
Mr. Edward J. Hejlek Esq., J.D.Exec. VP of Intellectual Property549.83k717.77k1956
Dr. Dawn Parsell Ph.D.Exec. VP of Clinical Devel.578.62k1.98M1963
Dr. Susannah Cantrell Ph.D.Exec. VP & Chief Commercial Officer625.47kN/A1970
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). The company has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Corporate Governance

Tricida, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.